Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3040 in Healthy and Overweight or Obese Participants
NCT07765160Phase 1Not yet recruiting
- Sponsor
- Innovent Biologics
- Start
- Aug 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of IBI3040 in obesity and Overweight (3 arms), sponsored by Innovent Biologics. Primary endpoints: Incidence rate of adverse events at 20 weeks, Incidence rate of serious adverse events at 20 weeks and 4 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
IBI3040
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07765160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07765160.